Back to search results

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Solid Tumors With MAPK Pathway Mutations

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • D3 Bio Investigative Site, Detroit, Michigan, United States

  • D3 Bio Investigative Site, New York, New York, United States

  • D3 Bio Investigative Site, Nashville, Tennessee, United States

  • D3 Bio Investigative Site, Blacktown, New South Wales, Australia

  • D3 Bio Investigative Site, Macquarie Park, New South Wales, Australia

  • D3 Bio Investigative Site, Bedford Park, South Australia, Australia

  • D3 Bio Investigative Site, Nedlands, Western Australia, Australia

  • D3 Bio Investigative Site, Beijing, Beijing Municipality, China

  • D3 Bio Investigative Site, Guangzhou, Guangdong, China

  • D3 Bio Investigative Site, Harbin, Heilong Jiang, China

  • D3 Bio Investigative Site, Wuhan, Hubei, China

  • D3 Bio Investigative Site, Shanghai, Shanghai Municipality, China

  • D3 Bio Investigative Site, Hangzhou, Zhejiang, China

  • D3 Bio Investigative Site, Seoul, South Korea

View source on ClinicalTrials.gov(opens in a new tab)